Phase I--study with aprosulate, a new synthetic anticoagulant.

摘要: This paper describes the first human study with aprosulate, a new chemically synthesized anticoagulant defined molecular structure and weight of 2388. Twelve healthy male volunteers received subcutaneous injections placebo on day followed by ascending doses aprosulate in range 0.25 mg/kg to 2.0 body alternate days. Anticoagulant, pharmacokinetic safety parameters were assessed for 48 hours after each injection. The activated partial thromboplastin time Heptest showed dose-dependent increase up ten application. A trend towards prolongation bleeding was indicated higher doses. In general, tolerance good. Plasma transaminase concentrations raised some but returned spontaneously normal during or study.